Protara Therapeutics, Inc. (TARA) 10-Year Financial Performance & Capital Metrics

TARA • • Industrial / General

HealthcareBiotechnologyOncology TherapeuticsSolid Tumor Oncology

AboutProtara Therapeutics, Inc., a clinical-stage biopharmaceutical company, engages in the identifying and advancing transformative therapies for the treatment of cancer and rare diseases. The company's lead program is TARA-002, an investigational cell therapy for the treatment of lymphatic malformations. It also develops intravenous choline chloride, an investigational phospholipid substrate replacement therapy for the treatment of intestinal failure associated liver disease. The company was formerly known as ArTara Therapeutics, Inc. and changed its name to Protara Therapeutics, Inc. in May 2020. Protara Therapeutics, Inc. is headquartered in New York, New York.Show more

Revenue $0
EBITDA -$49M -12.8%
Net Income -$45M -10.3%
EPS (Diluted) -2.17 +39.2%
Gross Margin -
EBITDA Margin -
Operating Margin -
Net Margin -
ROE -37.88% +20.2%
ROIC -171.38% -210.6%
Debt/Equity 0.03 -66.5%
Interest Coverage -

Technical Analysis

Key Insights

Based on financial data analysis

✓Strengths

✓Company is almost debt free
✓Momentum leader: RS Rating 84 (top 16%)
✓Trading at only 0.6x book value

✗Weaknesses

✗Shares diluted 81.7% in last year
✗Trading more than 30% below 52-week high
✗Low asset turnover indicates capital-intensive operations

Price & Volume

Loading chart...

Growth Metrics

Revenue CAGR

10Y-

5Y-

3Y-

TTM-

Profit (Net Income) CAGR

10Y-

5Y-

3Y-

TTM-25.81%

EPS CAGR

10Y-

5Y-

3Y-

TTM49.29%

ROCE

10Y Avg-57.27%

5Y Avg-39.3%

3Y Avg-45.8%

Latest-40.41%

Peer Comparison

Solid Tumor Oncology

Name	Market Cap	Current Price	P/E Ratio	Revenue Growth 1Y	Net Margin	ROE	FCF Yield	Debt/Equity
TLXTelix Pharmaceuticals Limited	2.49B	7.43	53.07	55.85%	3.98%	15.63%	0.36%	1.02
EXELExelixis, Inc.	12.18B	45.44	25.82	18.49%	29.63%	31.37%	5.2%	0.09
BBOTBridgeBio Oncology Therapeutics Inc.	919.87M	11.50	25			-25.73%
INBXInhibrx Biosciences, Inc.	1.04B	71.80	0.62	-88.89%	-110.78%	-421.09%		0.06
NUVBNuvation Bio Inc.	2.1B	6.14	-2.91		-8.13%	-66.74%		0.02
RLAYRelay Therapeutics, Inc.	1.32B	7.63	-3.23	-60.83%	-26.71%	-48.97%		0.06
ORICORIC Pharmaceuticals, Inc.	1.12B	11.52	-6.30			-33.24%		0.01
ZLABZai Lab Limited	2.09B	18.82	-7.24	49.59%	-46.83%	-27.21%		0.18

Profit & Loss

	Dec 2015	Dec 2016	Dec 2017	Dec 2018	Dec 2019	Dec 2020	Dec 2021	Dec 2022	Dec 2023	Dec 2024
Sales/Revenue+	0	0	0	0	0	0	0	0	0	0
Revenue Growth %	-1%	-	-	-	-	-	-	-	-	-
Cost of Goods Sold+	57K	123K	148K	115K	16K	196K	0	0	341K	0
COGS % of Revenue	-	-	-	-	-	-	-	-	-	-
Gross Profit+	-57K	-123K	-148K	-115K	-16K	-196K	0	0	-341K	0
Gross Margin %	-	-	-	-	-	-	-	-	-	-
Gross Profit Growth %	-1.02%	-1.16%	-0.2%	0.22%	0.86%	-11.25%	1%	-	-	1%
Operating Expenses+	20.81M	28.58M	30.21M	26.08M	15.25M	34.25M	47.49M	67.06M	43.27M	49.15M
OpEx % of Revenue	-	-	-	-	-	-	-	-	-	-
Selling, General & Admin	8.43M	9.71M	8.53M	10.57M	8.82M	22.36M	26.4M	20.74M	18.62M	17.45M
SG&A % of Revenue	-	-	-	-	-	-	-	-	-	-
Research & Development	12.38M	18.87M	21.69M	15.51M	6.44M	11.88M	21.09M	16.81M	24.79M	31.7M
R&D % of Revenue	-	-	-	-	-	-	-	-	-	-
Other Operating Expenses	0	0	0	207K	0	0	0	29.52M	-137K	0
Operating Income+	-20.87M	-28.7M	-30.36M	-26.08M	-15.25M	-34.44M	-47.49M	-67.06M	-43.61M	-49.15M
Operating Margin %	-	-	-	-	-	-	-	-	-	-
Operating Income Growth %	-1.75%	-0.38%	-0.06%	0.14%	0.42%	-1.26%	-0.38%	-0.41%	0.35%	-0.13%
EBITDA+	-20.81M	-28.58M	-30.21M	-25.96M	-15.24M	-34.25M	-47.37M	-66.81M	-43.27M	-48.82M
EBITDA Margin %	-	-	-	-	-	-	-	-	-	-
EBITDA Growth %	-1.76%	-0.37%	-0.06%	0.14%	0.41%	-1.25%	-0.38%	-0.41%	0.35%	-0.13%
D&A (Non-Cash Add-back)	57K	123K	148K	115K	16K	196K	117K	248K	341K	332K
EBIT	-21.38M	-28.53M	-29.96M	-20.73M	-7.83M	-33.98M	-45.52M	-64.81M	-43.61M	-49.15M
Net Interest Income+	0	0	0	0	0	432K	-1.5M	-27K	2.73M	4.13M
Interest Income	0	0	0	0	0	466K	237K	1.11M	2.73M	4.13M
Interest Expense	144K	193K	259K	0	0	34K	1.74M	1.14M	0	0
Other Income/Expense	-507K	179K	398K	643K	0	466K	237K	1.11M	3.19M	4.56M
Pretax Income+	-21.38M	-28.53M	-29.96M	-25.44M	-14.99M	-33.98M	-47.25M	-65.95M	-40.42M	-44.6M
Pretax Margin %	-	-	-	-	-	-	-	-	-	-
Income Tax+	0	0	0	5.35M	-262K	0	0	0	0	0
Effective Tax Rate %	1%	1%	1%	1%	1%	1%	1%	1%	1%	1%
Net Income+	-21.38M	-28.53M	-29.96M	-25.44M	-14.99M	-33.98M	-47.25M	-65.95M	-40.42M	-44.6M
Net Margin %	-	-	-	-	-	-	-	-	-	-
Net Income Growth %	-5.4%	-0.33%	-0.05%	0.15%	0.41%	-1.27%	-0.39%	-0.4%	0.39%	-0.1%
Net Income (Continuing)	-21.38M	-28.53M	-29.96M	-20.73M	-7.83M	-33.98M	-47.25M	-65.95M	-40.42M	-44.6M
Discontinued Operations	0	0	0	0	0	0	0	0	0	0
Minority Interest	0	0	0	0	0	0	0	0	0	0
EPS (Diluted)+	-51.94	-68.90	-69.38	-9.93	-3.63	-4.70	-4.20	-5.86	-3.57	-2.17
EPS Growth %	-4.07%	-0.33%	-0.01%	0.86%	0.63%	-0.29%	0.11%	-0.4%	0.39%	0.39%
EPS (Basic)	-51.94	-68.90	-69.38	-9.93	-3.63	-4.70	-4.20	-5.86	-3.57	-2.17
Diluted Shares Outstanding	411.6K	414.04K	431.86K	2.56M	4.06M	7.23M	11.23M	11.26M	11.33M	20.59M
Basic Shares Outstanding	411.6K	414.04K	431.86K	2.56M	4.06M	7.23M	11.23M	11.26M	11.33M	20.59M
Dividend Payout Ratio	-	-	-	-	-	-	-	-	-	-

Balance Sheet

	Dec 2015	Dec 2016	Dec 2017	Dec 2018	Dec 2019	Dec 2020	Dec 2021	Dec 2022	Dec 2023	Dec 2024
Total Current Assets+	66.61M	42.76M	43.48M	23.24M	6.97M	169.44M	93.11M	86.15M	68.7M	172.16M
Cash & Short-Term Investments	65.26M	41.32M	42.14M	21.87M	6.18M	168.6M	91.23M	84.37M	65.58M	170.29M
Cash Only	40.03M	36.39M	21.17M	19.37M	6.18M	168.6M	35.72M	24.13M	39.59M	162.8M
Short-Term Investments	25.23M	4.92M	20.97M	2.5M	0	0	55.51M	60.24M	25.99M	7.49M
Accounts Receivable	0	0	0	0	0	0	634K	486K	242K	0
Days Sales Outstanding	-	-	-	-	-	-	-	-	-	-
Inventory	0	0	0	0	0	0	0	1.16M	0	0
Days Inventory Outstanding	-	-	-	-	-	-	-	-	-	-
Other Current Assets	26.58M	6.36M	22.31M	0	716K	102K	34K	-1.04M	37K	2K
Total Non-Current Assets+	930K	765K	499K	285K	581K	33.72M	79.48M	27.14M	10.25M	9.3M
Property, Plant & Equipment	224K	372K	259K	263K	459K	2.3M	8.89M	7.87M	6.56M	5.28M
Fixed Asset Turnover	-	-	-	-	-	-	-	-	-	-
Goodwill	0	0	0	0	0	29.52M	29.52M	0	0	0
Intangible Assets	0	0	0	0	0	0	0	84K	2.66M	3.25M
Long-Term Investments	0	0	0	0	0	0	39.47M	17.89M	0	0
Other Non-Current Assets	706K	393K	240K	22K	122K	1.91M	1.61M	1.3M	1.03M	772K
Total Assets+	67.54M	43.52M	43.98M	23.52M	6.97M	203.16M	172.6M	113.29M	78.95M	181.45M
Asset Turnover	-	-	-	-	-	-	-	-	-	-
Asset Growth %	-0.2%	-0.36%	0.01%	-0.47%	-0.7%	28.13%	-0.15%	-0.34%	-0.3%	1.3%
Total Current Liabilities+	4.13M	5.08M	9.24M	3.08M	583K	2.92M	4.3M	5.74M	6.15M	10.96M
Accounts Payable	0	0	0	441K	716K	914K	954K	1.59M	2.43M	4.43M
Days Payables Outstanding	-	-	-	1.4K	16.33K	1.7K	-	-	2.61K	-
Short-Term Debt	0	0	20K	0	0	0	0	0	0	0
Deferred Revenue (Current)	0	0	-28.06K	0	0	0	0	0	0	0
Other Current Liabilities	4.13M	3.94M	7.89M	0	-137K	1.53M	1.8M	2.54M	2.11M	2.53M
Current Ratio	16.12x	8.42x	4.71x	7.55x	11.96x	58.13x	21.66x	15.01x	11.17x	15.71x
Quick Ratio	16.12x	8.42x	4.71x	7.55x	11.96x	58.13x	21.66x	14.81x	11.17x	15.71x
Cash Conversion Cycle	-	-	-	-	-	-	-	-	-	-
Total Non-Current Liabilities+	0	0	0	0	0	999K	6.38M	5.47M	4.48M	3.36M
Long-Term Debt	0	0	0	0	0	0	0	0	0	0
Capital Lease Obligations	0	0	0	0	0	999K	6.38M	5.47M	4.48M	3.36M
Deferred Tax Liabilities	0	0	0	0	0	0	0	0	0	0
Other Non-Current Liabilities	0	0	0	0	0	0	0	0	0	0
Total Liabilities	4.13M	5.08M	9.24M	3.08M	583K	3.91M	10.68M	11.21M	10.63M	14.32M
Total Debt+	0	0	20K	0	0	1.09M	7.24M	6.38M	5.47M	4.48M
Net Debt	-40.03M	-36.39M	-21.15M	-19.37M	-6.18M	-167.51M	-28.48M	-17.74M	-34.12M	-158.31M
Debt / Equity	-	-	0.00x	-	-	0.01x	0.04x	0.06x	0.08x	0.03x
Debt / EBITDA	-	-	-	-	-	-	-	-	-	-
Net Debt / EBITDA	-	-	-	-	-	-	-	-	-	-
Interest Coverage	-144.93x	-148.73x	-117.23x	-	-	-1013.06x	-27.34x	-58.98x	-	-
Total Equity+	63.41M	38.44M	34.74M	20.44M	6.39M	199.24M	161.91M	102.08M	68.32M	167.13M
Equity Growth %	-0.23%	-0.39%	-0.1%	-0.41%	-0.69%	30.17%	-0.19%	-0.37%	-0.33%	1.45%
Book Value per Share	154.04	92.84	80.44	7.98	1.57	27.54	14.41	9.07	6.03	8.12
Total Shareholders' Equity	63.41M	38.44M	34.74M	20.44M	6.39M	199.24M	161.91M	102.08M	68.32M	167.13M
Common Stock	16K	17K	18K	19K	3K	11K	11K	11K	11K	35K
Retained Earnings	-131.25M	-159.78M	-189.74M	-210.47M	-225.46M	-46.76M	-94.01M	-159.96M	-200.38M	-244.98M
Treasury Stock	0	0	202.26M	0	0	0	0	0	0	0
Accumulated OCI	-11K	-565K	-14K	5K	3K	0	-211K	-688K	-31K	2K
Minority Interest	0	0	0	0	0	0	0	0	0	0

Cash Flow

	Dec 2015	Dec 2016	Dec 2017	Dec 2018	Dec 2019	Dec 2020	Dec 2021	Dec 2022	Dec 2023	Dec 2024
Cash from Operations+	-17.57M	-23.69M	-22.35M	-23.23M	-15.65M	-23.41M	-34.5M	-26.46M	-37.56M	-35.81M
Operating CF Margin %	-	-	-	-	-	-	-	-	-	-
Operating CF Growth %	-0.76%	-0.35%	0.06%	-0.04%	0.33%	-0.5%	-0.47%	0.23%	-0.42%	0.05%
Net Income	-21.38M	-28.53M	-29.96M	-20.73M	-14.99M	-33.98M	-47.25M	-65.95M	-40.42M	-44.6M
Depreciation & Amortization	57K	123K	148K	115K	279K	196K	117K	248K	341K	332K
Stock-Based Compensation	2.16M	3.34M	926	3.43M	943K	9.75M	10.36M	6.69M	6.09M	4.13M
Deferred Taxes	0	0	0	0	0	-9.94M	0	0	0	0
Other Non-Cash Items	3.57M	3.69M	3.39M	-76K	-4K	9.94M	1.74M	32.02M	569K	324K
Working Capital Changes	327K	1.29M	4.41M	-5.97M	-1.87M	629K	534K	539K	-4.14M	4.01M
Change in Receivables	-32K	-26K	-46K	49K	17K	0	0	0	0	0
Change in Inventory	-83.49M	-63.52M	-41.79M	0	-17K	0	0	0	0	0
Change in Payables	1.26M	1.07M	4.16M	-6.16M	-2.5M	198K	40K	631K	848K	1.38M
Cash from Investing+	-11.33M	19.92M	-16.1M	18.43M	2.48M	2.83M	-98.19M	14.95M	53.11M	19.16M
Capital Expenditures	-198K	-271K	-35K	-119K	-16K	-884K	-596K	-120K	-45K	-63K
CapEx % of Revenue	-	-	-	-	-	-	-	-	-	-
Acquisitions	-	-	-	-	-	-	-	-	-	-
Investments	-	-	-	-	-	-	-	-	-	-
Other Investing	2.01M	0	0	0	0	0	-97.6K	15.07K	0	0
Cash from Financing+	163K	208K	23.05M	2.98M	500K	189.4M	-228K	-90K	-91K	139.87M
Debt Issued (Net)	-	-	-	-	-	-	-	-	-	-
Equity Issued (Net)	-	-	-	-	-	-	-	-	-	-
Dividends Paid	0	0	0	0	0	0	0	0	0	0
Share Repurchases	-	-	-	-	-	-	-	-	-	-
Other Financing	0	0	21.52M	132K	0	11.62M	0	0	0	3.86M
Net Change in Cash	-	-	-	-	-	-	-	-	-	-
Free Cash Flow+	-17.76M	-23.96M	-22.39M	-23.35M	-15.66M	-24.29M	-35.1M	-26.58M	-37.6M	-35.87M
FCF Margin %	-	-	-	-	-	-	-	-	-	-
FCF Growth %	-0.77%	-0.35%	0.07%	-0.04%	0.33%	-0.55%	-0.44%	0.24%	-0.41%	0.05%
FCF per Share	-43.16	-57.86	-51.84	-9.12	-3.86	-3.36	-3.12	-2.36	-3.32	-1.74
FCF Conversion (FCF/Net Income)	0.82x	0.83x	0.75x	0.91x	1.04x	0.69x	0.73x	0.40x	0.93x	0.80x
Interest Paid	0	0	0	0	0	0	0	0	0	0
Taxes Paid	0	0	0	0	0	0	0	0	0	0

Key Ratios

Metric	2015	2016	2017	2018	2019	2020	2021	2022	2023	2024
Return on Equity (ROE)	-29.31%	-56.02%	-81.89%	-92.19%	-111.73%	-33.05%	-26.17%	-49.96%	-47.44%	-37.88%
Return on Invested Capital (ROIC)	-84.62%	-169.36%	-291.23%	-266.83%	-1783.4%	-161.74%	-43.13%	-46.19%	-55.19%	-171.38%
Debt / Equity	-	-	0.00x	-	-	0.01x	0.04x	0.06x	0.08x	0.03x
Interest Coverage	-144.93x	-148.73x	-117.23x	-	-	-1013.06x	-27.34x	-58.98x	-	-
FCF Conversion	0.82x	0.83x	0.75x	0.91x	1.04x	0.69x	0.73x	0.40x	0.93x	0.80x
Revenue Growth	-100%	-	-	-	-	-	-	-	-	-

Frequently Asked Questions

Growth & Financials

Protara Therapeutics, Inc. (TARA) grew revenue by 0.0% over the past year. Growth has been modest.

Protara Therapeutics, Inc. (TARA) reported a net loss of $52.9M for fiscal year 2024.

Dividend & Returns

Protara Therapeutics, Inc. (TARA) has a return on equity (ROE) of -37.9%. Negative ROE indicates the company is unprofitable.

Protara Therapeutics, Inc. (TARA) had negative free cash flow of $48.8M in fiscal year 2024, likely due to heavy capital investments.

US Stock Screener

...

Protara Therapeutics, Inc. (TARA) 10-Year Financial Performance & Capital Metrics

TARA • • Industrial / General

HealthcareBiotechnologyOncology TherapeuticsSolid Tumor Oncology

Revenue $0
EBITDA -$49M -12.8%
Net Income -$45M -10.3%
EPS (Diluted) -2.17 +39.2%
Gross Margin -
EBITDA Margin -
Operating Margin -
Net Margin -
ROE -37.88% +20.2%
ROIC -171.38% -210.6%
Debt/Equity 0.03 -66.5%
Interest Coverage -

Technical Analysis

Key Insights

Based on financial data analysis

✓Strengths

✓Company is almost debt free
✓Momentum leader: RS Rating 84 (top 16%)
✓Trading at only 0.6x book value

✗Weaknesses

✗Shares diluted 81.7% in last year
✗Trading more than 30% below 52-week high
✗Low asset turnover indicates capital-intensive operations

Price & Volume

Loading chart...

Growth Metrics

Revenue CAGR

10Y-

5Y-

3Y-

TTM-

Profit (Net Income) CAGR

10Y-

5Y-

3Y-

TTM-25.81%

EPS CAGR

10Y-

5Y-

3Y-

TTM49.29%

ROCE

10Y Avg-57.27%

5Y Avg-39.3%

3Y Avg-45.8%

Latest-40.41%

Peer Comparison

Solid Tumor Oncology

Name	Market Cap	Current Price	P/E Ratio	Revenue Growth 1Y	Net Margin	ROE	FCF Yield	Debt/Equity
TLXTelix Pharmaceuticals Limited	2.49B	7.43	53.07	55.85%	3.98%	15.63%	0.36%	1.02
EXELExelixis, Inc.	12.18B	45.44	25.82	18.49%	29.63%	31.37%	5.2%	0.09
BBOTBridgeBio Oncology Therapeutics Inc.	919.87M	11.50	25			-25.73%
INBXInhibrx Biosciences, Inc.	1.04B	71.80	0.62	-88.89%	-110.78%	-421.09%		0.06
NUVBNuvation Bio Inc.	2.1B	6.14	-2.91		-8.13%	-66.74%		0.02
RLAYRelay Therapeutics, Inc.	1.32B	7.63	-3.23	-60.83%	-26.71%	-48.97%		0.06
ORICORIC Pharmaceuticals, Inc.	1.12B	11.52	-6.30			-33.24%		0.01
ZLABZai Lab Limited	2.09B	18.82	-7.24	49.59%	-46.83%	-27.21%		0.18

Profit & Loss

	Dec 2015	Dec 2016	Dec 2017	Dec 2018	Dec 2019	Dec 2020	Dec 2021	Dec 2022	Dec 2023	Dec 2024
Sales/Revenue+	0	0	0	0	0	0	0	0	0	0
Revenue Growth %	-1%	-	-	-	-	-	-	-	-	-
Cost of Goods Sold+	57K	123K	148K	115K	16K	196K	0	0	341K	0
COGS % of Revenue	-	-	-	-	-	-	-	-	-	-
Gross Profit+	-57K	-123K	-148K	-115K	-16K	-196K	0	0	-341K	0
Gross Margin %	-	-	-	-	-	-	-	-	-	-
Gross Profit Growth %	-1.02%	-1.16%	-0.2%	0.22%	0.86%	-11.25%	1%	-	-	1%
Operating Expenses+	20.81M	28.58M	30.21M	26.08M	15.25M	34.25M	47.49M	67.06M	43.27M	49.15M
OpEx % of Revenue	-	-	-	-	-	-	-	-	-	-
Selling, General & Admin	8.43M	9.71M	8.53M	10.57M	8.82M	22.36M	26.4M	20.74M	18.62M	17.45M
SG&A % of Revenue	-	-	-	-	-	-	-	-	-	-
Research & Development	12.38M	18.87M	21.69M	15.51M	6.44M	11.88M	21.09M	16.81M	24.79M	31.7M
R&D % of Revenue	-	-	-	-	-	-	-	-	-	-
Other Operating Expenses	0	0	0	207K	0	0	0	29.52M	-137K	0
Operating Income+	-20.87M	-28.7M	-30.36M	-26.08M	-15.25M	-34.44M	-47.49M	-67.06M	-43.61M	-49.15M
Operating Margin %	-	-	-	-	-	-	-	-	-	-
Operating Income Growth %	-1.75%	-0.38%	-0.06%	0.14%	0.42%	-1.26%	-0.38%	-0.41%	0.35%	-0.13%
EBITDA+	-20.81M	-28.58M	-30.21M	-25.96M	-15.24M	-34.25M	-47.37M	-66.81M	-43.27M	-48.82M
EBITDA Margin %	-	-	-	-	-	-	-	-	-	-
EBITDA Growth %	-1.76%	-0.37%	-0.06%	0.14%	0.41%	-1.25%	-0.38%	-0.41%	0.35%	-0.13%
D&A (Non-Cash Add-back)	57K	123K	148K	115K	16K	196K	117K	248K	341K	332K
EBIT	-21.38M	-28.53M	-29.96M	-20.73M	-7.83M	-33.98M	-45.52M	-64.81M	-43.61M	-49.15M
Net Interest Income+	0	0	0	0	0	432K	-1.5M	-27K	2.73M	4.13M
Interest Income	0	0	0	0	0	466K	237K	1.11M	2.73M	4.13M
Interest Expense	144K	193K	259K	0	0	34K	1.74M	1.14M	0	0
Other Income/Expense	-507K	179K	398K	643K	0	466K	237K	1.11M	3.19M	4.56M
Pretax Income+	-21.38M	-28.53M	-29.96M	-25.44M	-14.99M	-33.98M	-47.25M	-65.95M	-40.42M	-44.6M
Pretax Margin %	-	-	-	-	-	-	-	-	-	-
Income Tax+	0	0	0	5.35M	-262K	0	0	0	0	0
Effective Tax Rate %	1%	1%	1%	1%	1%	1%	1%	1%	1%	1%
Net Income+	-21.38M	-28.53M	-29.96M	-25.44M	-14.99M	-33.98M	-47.25M	-65.95M	-40.42M	-44.6M
Net Margin %	-	-	-	-	-	-	-	-	-	-
Net Income Growth %	-5.4%	-0.33%	-0.05%	0.15%	0.41%	-1.27%	-0.39%	-0.4%	0.39%	-0.1%
Net Income (Continuing)	-21.38M	-28.53M	-29.96M	-20.73M	-7.83M	-33.98M	-47.25M	-65.95M	-40.42M	-44.6M
Discontinued Operations	0	0	0	0	0	0	0	0	0	0
Minority Interest	0	0	0	0	0	0	0	0	0	0
EPS (Diluted)+	-51.94	-68.90	-69.38	-9.93	-3.63	-4.70	-4.20	-5.86	-3.57	-2.17
EPS Growth %	-4.07%	-0.33%	-0.01%	0.86%	0.63%	-0.29%	0.11%	-0.4%	0.39%	0.39%
EPS (Basic)	-51.94	-68.90	-69.38	-9.93	-3.63	-4.70	-4.20	-5.86	-3.57	-2.17
Diluted Shares Outstanding	411.6K	414.04K	431.86K	2.56M	4.06M	7.23M	11.23M	11.26M	11.33M	20.59M
Basic Shares Outstanding	411.6K	414.04K	431.86K	2.56M	4.06M	7.23M	11.23M	11.26M	11.33M	20.59M
Dividend Payout Ratio	-	-	-	-	-	-	-	-	-	-

Balance Sheet

	Dec 2015	Dec 2016	Dec 2017	Dec 2018	Dec 2019	Dec 2020	Dec 2021	Dec 2022	Dec 2023	Dec 2024
Total Current Assets+	66.61M	42.76M	43.48M	23.24M	6.97M	169.44M	93.11M	86.15M	68.7M	172.16M
Cash & Short-Term Investments	65.26M	41.32M	42.14M	21.87M	6.18M	168.6M	91.23M	84.37M	65.58M	170.29M
Cash Only	40.03M	36.39M	21.17M	19.37M	6.18M	168.6M	35.72M	24.13M	39.59M	162.8M
Short-Term Investments	25.23M	4.92M	20.97M	2.5M	0	0	55.51M	60.24M	25.99M	7.49M
Accounts Receivable	0	0	0	0	0	0	634K	486K	242K	0
Days Sales Outstanding	-	-	-	-	-	-	-	-	-	-
Inventory	0	0	0	0	0	0	0	1.16M	0	0
Days Inventory Outstanding	-	-	-	-	-	-	-	-	-	-
Other Current Assets	26.58M	6.36M	22.31M	0	716K	102K	34K	-1.04M	37K	2K
Total Non-Current Assets+	930K	765K	499K	285K	581K	33.72M	79.48M	27.14M	10.25M	9.3M
Property, Plant & Equipment	224K	372K	259K	263K	459K	2.3M	8.89M	7.87M	6.56M	5.28M
Fixed Asset Turnover	-	-	-	-	-	-	-	-	-	-
Goodwill	0	0	0	0	0	29.52M	29.52M	0	0	0
Intangible Assets	0	0	0	0	0	0	0	84K	2.66M	3.25M
Long-Term Investments	0	0	0	0	0	0	39.47M	17.89M	0	0
Other Non-Current Assets	706K	393K	240K	22K	122K	1.91M	1.61M	1.3M	1.03M	772K
Total Assets+	67.54M	43.52M	43.98M	23.52M	6.97M	203.16M	172.6M	113.29M	78.95M	181.45M
Asset Turnover	-	-	-	-	-	-	-	-	-	-
Asset Growth %	-0.2%	-0.36%	0.01%	-0.47%	-0.7%	28.13%	-0.15%	-0.34%	-0.3%	1.3%
Total Current Liabilities+	4.13M	5.08M	9.24M	3.08M	583K	2.92M	4.3M	5.74M	6.15M	10.96M
Accounts Payable	0	0	0	441K	716K	914K	954K	1.59M	2.43M	4.43M
Days Payables Outstanding	-	-	-	1.4K	16.33K	1.7K	-	-	2.61K	-
Short-Term Debt	0	0	20K	0	0	0	0	0	0	0
Deferred Revenue (Current)	0	0	-28.06K	0	0	0	0	0	0	0
Other Current Liabilities	4.13M	3.94M	7.89M	0	-137K	1.53M	1.8M	2.54M	2.11M	2.53M
Current Ratio	16.12x	8.42x	4.71x	7.55x	11.96x	58.13x	21.66x	15.01x	11.17x	15.71x
Quick Ratio	16.12x	8.42x	4.71x	7.55x	11.96x	58.13x	21.66x	14.81x	11.17x	15.71x
Cash Conversion Cycle	-	-	-	-	-	-	-	-	-	-
Total Non-Current Liabilities+	0	0	0	0	0	999K	6.38M	5.47M	4.48M	3.36M
Long-Term Debt	0	0	0	0	0	0	0	0	0	0
Capital Lease Obligations	0	0	0	0	0	999K	6.38M	5.47M	4.48M	3.36M
Deferred Tax Liabilities	0	0	0	0	0	0	0	0	0	0
Other Non-Current Liabilities	0	0	0	0	0	0	0	0	0	0
Total Liabilities	4.13M	5.08M	9.24M	3.08M	583K	3.91M	10.68M	11.21M	10.63M	14.32M
Total Debt+	0	0	20K	0	0	1.09M	7.24M	6.38M	5.47M	4.48M
Net Debt	-40.03M	-36.39M	-21.15M	-19.37M	-6.18M	-167.51M	-28.48M	-17.74M	-34.12M	-158.31M
Debt / Equity	-	-	0.00x	-	-	0.01x	0.04x	0.06x	0.08x	0.03x
Debt / EBITDA	-	-	-	-	-	-	-	-	-	-
Net Debt / EBITDA	-	-	-	-	-	-	-	-	-	-
Interest Coverage	-144.93x	-148.73x	-117.23x	-	-	-1013.06x	-27.34x	-58.98x	-	-
Total Equity+	63.41M	38.44M	34.74M	20.44M	6.39M	199.24M	161.91M	102.08M	68.32M	167.13M
Equity Growth %	-0.23%	-0.39%	-0.1%	-0.41%	-0.69%	30.17%	-0.19%	-0.37%	-0.33%	1.45%
Book Value per Share	154.04	92.84	80.44	7.98	1.57	27.54	14.41	9.07	6.03	8.12
Total Shareholders' Equity	63.41M	38.44M	34.74M	20.44M	6.39M	199.24M	161.91M	102.08M	68.32M	167.13M
Common Stock	16K	17K	18K	19K	3K	11K	11K	11K	11K	35K
Retained Earnings	-131.25M	-159.78M	-189.74M	-210.47M	-225.46M	-46.76M	-94.01M	-159.96M	-200.38M	-244.98M
Treasury Stock	0	0	202.26M	0	0	0	0	0	0	0
Accumulated OCI	-11K	-565K	-14K	5K	3K	0	-211K	-688K	-31K	2K
Minority Interest	0	0	0	0	0	0	0	0	0	0

Cash Flow

	Dec 2015	Dec 2016	Dec 2017	Dec 2018	Dec 2019	Dec 2020	Dec 2021	Dec 2022	Dec 2023	Dec 2024
Cash from Operations+	-17.57M	-23.69M	-22.35M	-23.23M	-15.65M	-23.41M	-34.5M	-26.46M	-37.56M	-35.81M
Operating CF Margin %	-	-	-	-	-	-	-	-	-	-
Operating CF Growth %	-0.76%	-0.35%	0.06%	-0.04%	0.33%	-0.5%	-0.47%	0.23%	-0.42%	0.05%
Net Income	-21.38M	-28.53M	-29.96M	-20.73M	-14.99M	-33.98M	-47.25M	-65.95M	-40.42M	-44.6M
Depreciation & Amortization	57K	123K	148K	115K	279K	196K	117K	248K	341K	332K
Stock-Based Compensation	2.16M	3.34M	926	3.43M	943K	9.75M	10.36M	6.69M	6.09M	4.13M
Deferred Taxes	0	0	0	0	0	-9.94M	0	0	0	0
Other Non-Cash Items	3.57M	3.69M	3.39M	-76K	-4K	9.94M	1.74M	32.02M	569K	324K
Working Capital Changes	327K	1.29M	4.41M	-5.97M	-1.87M	629K	534K	539K	-4.14M	4.01M
Change in Receivables	-32K	-26K	-46K	49K	17K	0	0	0	0	0
Change in Inventory	-83.49M	-63.52M	-41.79M	0	-17K	0	0	0	0	0
Change in Payables	1.26M	1.07M	4.16M	-6.16M	-2.5M	198K	40K	631K	848K	1.38M
Cash from Investing+	-11.33M	19.92M	-16.1M	18.43M	2.48M	2.83M	-98.19M	14.95M	53.11M	19.16M
Capital Expenditures	-198K	-271K	-35K	-119K	-16K	-884K	-596K	-120K	-45K	-63K
CapEx % of Revenue	-	-	-	-	-	-	-	-	-	-
Acquisitions	-	-	-	-	-	-	-	-	-	-
Investments	-	-	-	-	-	-	-	-	-	-
Other Investing	2.01M	0	0	0	0	0	-97.6K	15.07K	0	0
Cash from Financing+	163K	208K	23.05M	2.98M	500K	189.4M	-228K	-90K	-91K	139.87M
Debt Issued (Net)	-	-	-	-	-	-	-	-	-	-
Equity Issued (Net)	-	-	-	-	-	-	-	-	-	-
Dividends Paid	0	0	0	0	0	0	0	0	0	0
Share Repurchases	-	-	-	-	-	-	-	-	-	-
Other Financing	0	0	21.52M	132K	0	11.62M	0	0	0	3.86M
Net Change in Cash	-	-	-	-	-	-	-	-	-	-
Free Cash Flow+	-17.76M	-23.96M	-22.39M	-23.35M	-15.66M	-24.29M	-35.1M	-26.58M	-37.6M	-35.87M
FCF Margin %	-	-	-	-	-	-	-	-	-	-
FCF Growth %	-0.77%	-0.35%	0.07%	-0.04%	0.33%	-0.55%	-0.44%	0.24%	-0.41%	0.05%
FCF per Share	-43.16	-57.86	-51.84	-9.12	-3.86	-3.36	-3.12	-2.36	-3.32	-1.74
FCF Conversion (FCF/Net Income)	0.82x	0.83x	0.75x	0.91x	1.04x	0.69x	0.73x	0.40x	0.93x	0.80x
Interest Paid	0	0	0	0	0	0	0	0	0	0
Taxes Paid	0	0	0	0	0	0	0	0	0	0

Key Ratios

Metric	2015	2016	2017	2018	2019	2020	2021	2022	2023	2024
Return on Equity (ROE)	-29.31%	-56.02%	-81.89%	-92.19%	-111.73%	-33.05%	-26.17%	-49.96%	-47.44%	-37.88%
Return on Invested Capital (ROIC)	-84.62%	-169.36%	-291.23%	-266.83%	-1783.4%	-161.74%	-43.13%	-46.19%	-55.19%	-171.38%
Debt / Equity	-	-	0.00x	-	-	0.01x	0.04x	0.06x	0.08x	0.03x
Interest Coverage	-144.93x	-148.73x	-117.23x	-	-	-1013.06x	-27.34x	-58.98x	-	-
FCF Conversion	0.82x	0.83x	0.75x	0.91x	1.04x	0.69x	0.73x	0.40x	0.93x	0.80x
Revenue Growth	-100%	-	-	-	-	-	-	-	-	-

Frequently Asked Questions

Growth & Financials

Protara Therapeutics, Inc. (TARA) grew revenue by 0.0% over the past year. Growth has been modest.

Protara Therapeutics, Inc. (TARA) reported a net loss of $52.9M for fiscal year 2024.

Dividend & Returns

Protara Therapeutics, Inc. (TARA) has a return on equity (ROE) of -37.9%. Negative ROE indicates the company is unprofitable.

Protara Therapeutics, Inc. (TARA) had negative free cash flow of $48.8M in fiscal year 2024, likely due to heavy capital investments.